STING1 and neoplasm: To gain a further insight on the response of tumour ECs to STING agonist, we performed scRNA-seq on the ECs of MMTV-PyMT spontaneous tumour and its orthotopic implanted breast tumour, which were sampled at 3 h after i.t PBS or cGAMP (Fig. 8a).